INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
Boca Raton, Florida, October 21st, 2026, FinanceWire Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks US BLA expected to be submitted in Q2, 2027 INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel…
Read More